[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

December 2015, Vol 1, No. 9, Pages 1189-1353

Original Investigation

Use of Preoperative Magnetic Resonance Imaging for Breast Cancer: A Canadian Population-Based Study

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1238-1250. doi:10.1001/jamaoncol.2015.3018

This population-based cohort study used administrative heath care databases in Ontario, Canada, and determined that preoperative breast MRI use is associated with a significant increase in ancillary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomies.

Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study

Abstract Full Text
open access
JAMA Oncol. 2015;1(9):1251-1260. doi:10.1001/jamaoncol.2015.3048

This survey study found that despite improved knowledge, understanding, and satisfaction among patients who receive genetic counseling provided by a genetics clinician, as well as guidelines emphasizing genetic counseling, most US women undergoing BRCA testing do not receive this service.

Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1261-1269. doi:10.1001/jamaoncol.2015.2895

This systematic review and meta-analysis of 15 randomized clinical trials (6856 patients) finds that overall survival in intermittent androgen deprivation therapy for prostate cancer was not inferior to continuous therapy, and some quality-of-life criteria seemed improved with intermittent therapy.

First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2015;1(9):1272-1280. doi:10.1001/jamaoncol.2015.3101

This international, multicenter, phase 2b, open-label, randomized study evaluated the efficacy and safety of treatment with aldoxorubicin vs doxorubicin in patients with previously untreated locally advanced, unresectable, or metastatic soft-tissue sarcoma.

Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1282-1290. doi:10.1001/jamaoncol.2015.3209

This systematic review and meta-analysis identifies contemporary occupations associated with increased incidence of risk of bladder cancer risk; workers with aromatic amine exposure have the highest incidence, while those exposed to PAHs and heavy metals have the greatest mortality.

Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1293-1300. doi:10.1001/jamaoncol.2015.3316

This cost-effectiveness analysis of the SQUIRE trial findings and others evaluates incremental costs and patient life expectancies associated with adding necitumumab to standard chemotherapy as first-line treatment of metastatic squamous cell lung cancer.

Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage

Abstract Full Text
open access
JAMA Oncol. 2015;1(9):1303-1310. doi:10.1001/jamaoncol.2015.3151

This analysis and comparison of cancer treatment outcomes gleaned from 2 types of database records, those including and those not including staging information, finds that records without staging data might be adequate to accurately measure, at the hospital level, cancer survival outcomes.

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1311-1318. doi:10.1001/jamaoncol.2015.3062

This systematic review uses data from multiple medical databases and other sources to identify that sequential anthracycline-cyclophosphamide and taxane is likely the most effective adjuvant therapy for early-stage breast cancer.

Brief Report

Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1319-1323. doi:10.1001/jamaoncol.2015.2151

This genetic sequencing study investigated whether endometrial cancers with polymerase e mutations and microsatellite instability had increased neoantigen load, more tumor-infiltrating lymphocytes, and higher expression of PD-1 and PD-L1 than endometrial cancers without these characteristics.

Review

Role of Local Radiation Therapy in Cancer Immunotherapy

Abstract Full Text
JAMA Oncol. 2015;1(9):1325-1332. doi:10.1001/jamaoncol.2015.2756

This review examines growing evidence that radiation therapy targeted to the tumor can convert it into an in situ tumor vaccine by inducing release of antigens during cancer cell death in association with proinflammatory signals that trigger the innate immune system to activate tumor-specific T cells.

Hospitalizations During Systemic Therapy for Metastatic Lung Cancer: A Systematic Review of Real World vs Clinical Trial Outcomes

Abstract Full Text
JAMA Oncol. 2015;1(9):1333-1339. doi:10.1001/jamaoncol.2015.3440

This systematic review finds that few clinical trials in metastatic non–small-cell lung cancer report hospitalization information, but among those that do, hospitalization rates are consistently lower than in real world reports of similar patients undergoing similar therapies.

JAMA Oncology Clinical Challenge

Unexpected Cardiac Masses

Abstract Full Text
JAMA Oncol. 2015;1(9):1343-1344. doi:10.1001/jamaoncol.2015.3077

A woman in her 50s with intermittent epigastric pain, palpitations, and hot flashes had multiple intramyocardial masses involving the left ventricle, aortopulmonary window lymphadenopathy, and moderate pericardial effusion. What is your diagnosis?

Lymphadenopathy and Jaundice

Abstract Full Text
JAMA Oncol. 2015;1(9):1345-1346. doi:10.1001/jamaoncol.2015.2975

A man in his 20s had a large right supraclavicular lymph node, extensive mediastinal lymphadenopathy, a large extracardiac mass abutting the left atrium, hepatomegaly, and multiple splenic lesions. What is your diagnosis?

Viewpoint

Primary Tumor Resection in Metastatic Colorectal Cancer: Please Pass the Salt

Abstract Full Text
JAMA Oncol. 2015;1(9):1213-1214. doi:10.1001/jamaoncol.2015.2757

This Viewpoint discusses management of the primary tumor in asymptomatic patients with colorectal cancer.

Big Tobacco and Drugstore Chains: A Long, Cozy Relationship

Abstract Full Text
JAMA Oncol. 2015;1(9):1215-1216. doi:10.1001/jamaoncol.2015.2621

This viewpoint argues that drugstores, as providers of health care items and services, should be required by public pressure or legislative action to stop selling tobacco products, which harm people when used as indicated.

Cost-effectiveness of Universal BRCA1/2 Screening: Evidence-Based Decision Making

Abstract Full Text
JAMA Oncol. 2015;1(9):1217-1218. doi:10.1001/jamaoncol.2015.2340

This Viewpoint discusses whether a broad genetic testing program for BRCA1/2 is realistic in terms of the relative value and costs of such a program.

The Slippery Slope of Broadening Treatment Eligibility and Weak End Points: Defending the Oligo in Oligometastatic Non–Small-Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2015;1(9):1219-1220. doi:10.1001/jamaoncol.2015.2966

This Viewpoint details the importance of gathering evidence before clinically using unproven but financially attractive local therapies to treat oligometastatic non–small-cell lung cancer.

Moving Toward Economically Sustainable Value-Based Cancer Care in the Academic Setting

Abstract Full Text
JAMA Oncol. 2015;1(9):1221-1222. doi:10.1001/jamaoncol.2015.3449

Academic cancer centers play a vital role in cancer care in an increasingly cost-sensitive health care market, and proponents must emphasize the value-based clinical, research, and business contributions these centers can make to the eradication of cancer.

From the JAMA Network

Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy

Abstract Full Text
JAMA Oncol. 2015;1(9):1340-1341. doi:10.1001/jamaoncol.2015.2274

This commentary argues that while cutaneous adverse effects are associated with better outcomes among patients undergoing treatment with pembrolizumab, further analysis is required to determine whether nonvitiligo cutaneous adverse effects contribute to the observed outcome.

Editorial

Genetic Testing for BRCA Mutations Today and Tomorrow—About the ABOUT Study

Abstract Full Text
JAMA Oncol. 2015;1(9):1225-1226. doi:10.1001/jamaoncol.2015.3269

Rethinking Preoperative Breast Magnetic Resonance Imaging

Abstract Full Text
JAMA Oncol. 2015;1(9):1226-1227. doi:10.1001/jamaoncol.2015.3029
Invited Commentary

The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy

Abstract Full Text
JAMA Oncol. 2015;1(9):1270-1271. doi:10.1001/jamaoncol.2015.3005

Aldoxorubicin in Sarcoma: Teaching an Old Drug New Tricks

Abstract Full Text
JAMA Oncol. 2015;1(9):1280-1281. doi:10.1001/jamaoncol.2015.3221

The Need for Further Preventive Measures for Occupational Bladder Cancer

Abstract Full Text
JAMA Oncol. 2015;1(9):1291-1292. doi:10.1001/jamaoncol.2015.3270

Value-Based Cancer Care and the Excessive Cost of Drugs

Abstract Full Text
JAMA Oncol. 2015;1(9):1301-1302. doi:10.1001/jamaoncol.2015.3302
JAMA Oncology Patient Page

Cognitive Changes During Chemotherapy

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1353. doi:10.1001/jamaoncol.2015.4142
Cancer Care Chronicles

Work/Life Balance: A Tale of the Blue Collar Father and the White Collar Daughter

Abstract Full Text
JAMA Oncol. 2015;1(9):1223-1224. doi:10.1001/jamaoncol.2015.3347
Poetry and Oncology

I Hope

Abstract Full Text
JAMA Oncol. 2015;1(9):1250. doi:10.1001/jamaoncol.2015.4714
Correction

Error in Data

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1224. doi:10.1001/jamaoncol.2015.5120

Data Errors in Table

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1323. doi:10.1001/jamaoncol.2015.5375
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1203. doi:10.1001/jamaoncol.2014.252
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2015;1(9):1189. doi:10.1001/jamaoncol.2015.0730
×